Figure 5From: Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study Rate of decline in FEV 1 by baseline post-bronchodilator FEV 1 % predicted.Back to article page